| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.058 | 0.2 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | ML334 diastereomer | CTRPv2 | pan-cancer | AAC | -0.055 | 0.2 |
| mRNA | fluvastatin | CTRPv2 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | -0.057 | 0.2 |
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | pifithrin-alpha | CTRPv2 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.034 | 0.2 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | -0.21 | 0.2 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | -0.038 | 0.2 |